SANTA CLARA, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Applied Imaging
Corp. (Nasdaq: AICX) today announced the appointment of Robin C. Stracey to
the newly-created position of President and Chief Operating Officer. In this
role, Mr. Stracey will have responsibility for the Company's worldwide
commercial and product development activities.
    "We are extremely fortunate to have Robin joining our team," commented
Carl Hull, Chief Executive Officer of Applied Imaging. "With over 20 years of
diagnostic and life sciences experience, and his extensive international
operating background, Robin will be in a position to make an immediate
contribution to Applied Imaging's operations."
    Prior to joining Applied Imaging, Mr. Stracey was the Vice President and
General Manager of the Chromatography and Mass Spectrometry business unit of
Thermo Electron Corporation, where he was responsible for all aspects of a
$140 million business unit providing sophisticated capital equipment and
consumables to drug discovery, clinical and life sciences customers worldwide.
Mr. Stracey was also previously a Corporate Vice President of Dade Behring and
the General Manager of Syva Inc., a leading supplier of specialized diagnostic
reagents.
    Mr. Stracey has a bachelors of science degree with honors in life sciences
from the University of Nottingham in the United Kingdom. He is a graduate of
the Executive Program at the Stanford University Graduate School of Business.
    Commenting on his appointment, Mr. Stracey said, "I am very pleased to be
joining Applied Imaging at such an exciting time in the Company's development.
The commercial and clinical prospects for the Ariol(TM) automated pathology
system and the Company's well-established genetics systems are highly
promising."
    Mr. Stracey was granted an option to purchase up to 200,000 shares of the
Company's common stock, pursuant to the revised Nasdaq listing requirement
Rule 4350(i)(1)(A)(iv). The option will vest over a four-year period.

    About Applied Imaging
    Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories throughout the world for the analysis of chromosomes in cancer
and prenatal disorders. The Company markets a range of imaging systems for
fluorescence and brightfield microscopy applications, including the Company's
Ariol(TM), MDS(TM), SPOT(TM), CytoVision(R), PowerGene(R) and QUIPS(R) product
lines. Applied Imaging has installed in excess of 3,000 systems in over 1,000
laboratories in more than 60 countries.

    This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the outlook for the Company's Ariol automated pathology system and
its genetics systems. Forward looking statements address matters that are
subject to a number of risks, uncertainties and other factors, detailed in the
Company's periodic filings with the Securities and Exchange Commission
including, but not limited to, those risks and uncertainties listed in the
section entitled "Management's Discussion and Analysis of Financial Condition
and Results of Operations -- Factors Affecting Future Results," in Applied
Imaging's annual report on Form 10-K for the year ended December 31, 2002. The
forward-looking statements are made as of November 19, 2003, and Applied
Imaging is under no obligation to revise or update the forward-looking
statements.
    For additional information on Applied Imaging, visit the Company's Web
site at http://www.aicorp.com .

Link to this page: